Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Censored data

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44336   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    381 result(s) found for: Censored data. Displaying page 1 of 20.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2015-002340-14 Sponsor Protocol Number: REMAP-CAP Start Date*: 2015-09-16
    Sponsor Name:University Medical Center Utrecht
    Full Title: Randomized, Embedded, Multifactorial, Adaptive Platform trial for Community-Acquired Pneumonia (REMAP-CAP). (COVID-19)
    Medical condition: Severe Community Acquired Pneumonia COVID-19
    Disease: Version SOC Term Classification Code Term Level
    20.1 10021881 - Infections and infestations 10010120 Community acquired pneumonia LLT
    23.0 10021881 - Infections and infestations 10084268 COVID-19 PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Trial now transitioned) IE (Trial now transitioned) PT (Trial now transitioned) GB (GB - no longer in EU/EEA) HU (Completed) BE (Trial now transitioned) DE (Ongoing) HR (Trial now transitioned) ES (Temporarily Halted) FR (Trial now transitioned) FI (Ongoing) IT (Trial now transitioned) CZ (Trial now transitioned) SI (Trial now transitioned) RO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2006-004024-37 Sponsor Protocol Number: A6181109 Start Date*: 2007-07-05
    Sponsor Name:Pfizer Inc. - 235 East 42nd Street - New York - 10017
    Full Title: SUNITINIB TREATMENT OF RENAL ADJUVANT CANCER (S-TRAC): A RANDOMIZED DOUBLE-BLIND PHASE 3 STUDY OF ADJUVANT SUNITINIB VS. PLACEBO IN SUBJECTS WITH HIGH RISK RCC
    Medical condition: Adjuvant treatment of subjects with “high risk” Renal Cell Carcinoma (RCC) following nephrectomy.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10038408 Renal cell carcinomas HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) GB (Completed) CZ (Completed) DE (Completed) GR (Completed) AT (Completed) IT (Completed) IE (Completed) SE (Completed) PL (Completed) SK (Completed) DK (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2018-002090-21 Sponsor Protocol Number: DEDALO Start Date*: 2019-05-16
    Sponsor Name:Fondazione EMN Italy Onlus
    Full Title: Daratumumab, pomalidomide and dexamethasone for del(17p) positive relapsed and relapsed/refractory multiple myeloma patients [DEDALO]
    Medical condition: Multiple Myeloma patients with relapsed or relapsed/refractory disease with the presence of del(17p) in the plasma cell clone
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10028228 Multiple myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2014-004027-52 Sponsor Protocol Number: GINECO-OV125b Start Date*: 2015-11-30
    Sponsor Name:ARCAGY Research
    Full Title: Randomized, Double-Blind, Phase III Trial of Olaparib vs. Placebo in Patients with Advanced FIGO Stage IIIB – IV High Grade Serous or Endometrioid Ovarian, Fallopian Tube, or Peritoneal Cancer trea...
    Medical condition: Patients with advanced FIGO stage IIIB – IV high grade epithelial ovarian, fallopian tube, or peritoneal cancer treated with standard first-line treatment
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10070908 Ovarian cancer stage IV PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10070907 Ovarian cancer stage III PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DE (Ongoing) AT (Completed) BE (Completed) ES (Ongoing) DK (Completed) SE (Completed) FI (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2009-010715-32 Sponsor Protocol Number: 20080763 Start Date*: 2009-11-17
    Sponsor Name:Amgen Inc
    Full Title: A Randomized, Multicenter, Open-label, Phase 3 Study to Compare the Efficacy and Safety of Panitumumab and Cetuximab in Subjects with Previously Treated, Wild-type KRAS, Metastatic Colorectal Cancer
    Medical condition: Previously Treated, Wild-type KRAS, Metastatic Colorectal Cancer
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004864 10052362 Metastatic colorectal cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LV (Completed) FR (Completed) LT (Completed) CZ (Completed) SE (Completed) BE (Completed) SK (Completed) IT (Completed) NL (Completed) GB (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2014-002272-88 Sponsor Protocol Number: 54767414MMY3007 Start Date*: 2014-10-20
    Sponsor Name:Janssen-Cilag International N.V.
    Full Title: A Phase 3, Randomized, Controlled, Open-label Study of VELCADE (Bortezomib) Melphalan-Prednisone (VMP) Compared to Daratumumab in Combination with VMP (D-VMP), in Subjects with Previously Untreated...
    Medical condition: Multiple myeloma
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10028228 Multiple myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) BE (Completed) ES (Completed) CZ (Completed) IT (Completed) DE (Completed) BG (Completed) RO (Ongoing) PL (Completed) HR (Completed) GR (Completed) PT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-003590-10 Sponsor Protocol Number: HM19/123658 Start Date*: 2019-10-30
    Sponsor Name:University of Leeds
    Full Title: Frailty-adjusted therapy in Transplant Non-Eligible patients with newly diagnosed Multiple Myeloma: A phase III trial to compare standard and frailty-adjusted induction therapy with ixazomib, lena...
    Medical condition: Newly diagnosed multiple myeloma
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004851 10028229 Multiple myelomas HLT
    20.0 100000004864 10028566 Myeloma LLT
    21.0 100000004864 10028228 Multiple myeloma LLT
    21.0 100000004864 10028228 Multiple myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2020-003889-39 Sponsor Protocol Number: NALPAC Start Date*: 2021-10-11
    Sponsor Name:Belgian Group of Digestive Oncology (BGDO)
    Full Title: A Non-Comparative Randomized Phase 2 Study, Evaluating the Efficacy of 5-FU + NALIRI and 5-FU + NALIRINOX for Metastatic Pancreatic Ductal Adenocarcinoma (PDAC), Progressive After Gemcitabine-Abra...
    Medical condition: Pancreatic ductal adenocarcinoma (PDAC)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2017-001912-13 Sponsor Protocol Number: KTE-C19-105 Start Date*: 2018-04-24
    Sponsor Name:Kite Pharma, Inc.
    Full Title: A Phase 2 Multicenter Study of Axicabtagene Ciloleucel in Subjects with Relapsed/Refractory Indolent Non-Hodgkin Lymphoma (iNHL) (ZUMA-5)
    Medical condition: Relapsed or Refractory Indolent Non-Hodgkin Lymphoma (r/r) iNHL.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10065856 Non-Hodgkin's lymphoma unspecified histology indolent PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2018-000624-33 Sponsor Protocol Number: HO156_AMLSG28/18 Start Date*: 2019-08-01
    Sponsor Name:HOVON Foundation
    Full Title: A phase 3, multicenter, open-label, randomized, study of gilteritinib versus midostaurin in combination with induction and consolidation therapy followed by one-year maintenance in patients with ne...
    Medical condition: Previously untreated Acute Myeloid Leukemia (AML) or Myelodysplastic syndromes with excess blasts-2 (MDS-EB2) with FLT3 mutations
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10001941 AML LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10068361 MDS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Trial now transitioned) SE (Trial now transitioned) LT (Trial now transitioned) BE (Trial now transitioned) FI (Trial now transitioned) FR (Trial now transitioned) IE (Trial now transitioned) AT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2014-003863-40 Sponsor Protocol Number: D4193C00002 Start Date*: 2015-09-10
    Sponsor Name:AstraZeneca AB
    Full Title: A Phase III Randomized, Open-Label, Multi-Center, Global Study of MEDI4736 Monotherapy and MEDI4736 in Combination with Tremelimumab Versus Standard of Care Therapy in Patients with Recurrent or M...
    Medical condition: Recurrent or metastatic PD-L1-positive or negative squamous cell carcinoma of the head and neck (SCCHN).
    Disease: Version SOC Term Classification Code Term Level
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10067821 Head and neck cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) CZ (Completed) BE (Completed) DE (Completed) ES (Completed) FR (Completed) PL (Completed) RO (Completed) HR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2016-000617-67 Sponsor Protocol Number: IRFMN-MPM-7109 Start Date*: 2018-07-03
    Sponsor Name:IRCCS- ISTITUTO DI RICERCHE FARMACOLOGICHE MARIO NEGRI
    Full Title: A phase II study to investigate the activity and safety of anti-PD-L1 antibody (Durvalumab) In ADvancEd pretreated malignant pleural Mesothelioma - DIADEM Study
    Medical condition: Advanced malignant pleural mesothelioma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027406 Mesothelioma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2020-003091-40 Sponsor Protocol Number: EMN26 Start Date*: 2020-12-04
    Sponsor Name: European Myeloma Network – EMN
    Full Title: PHASE II STUDY OF IBERDOMIDE (CC220) MAINTENANCE AFTER AUTOLOGOUS STEM CELL TRANSPLANTATION IN NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS
    Medical condition: Newly diagnosed multiple myeloma
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10028228 Multiple myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GR (Trial now transitioned) NL (Trial now transitioned) FR (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2018-003520-37 Sponsor Protocol Number: RG_18-220 Start Date*: 2020-02-07
    Sponsor Name:University of Birmingham
    Full Title: A multi-stage randomised trial of durvalumab (Medi4736) with chemoradiotherapy with 5-fluorouracil and mitomycin C in patients with muscle-invasive bladder cancer
    Medical condition: Muscle invasive bladder cancer
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10022877 Invasive bladder cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2019-004388-37 Sponsor Protocol Number: 69HCL19_0457 Start Date*: 2020-03-03
    Sponsor Name:Hospices Civils de Lyon
    Full Title: A Three-Cohort Phase II trial to Assess the Efficacy of a Maintenance Treatment with TALAzoparib following First Line Platinum-based Chemotherapy in Pleural and Malignant Peritoneal MESOthelioma Pa...
    Medical condition: This study involves adults subjects with advanced malignant pleural (cohort A) or peritoneal (cohorts B1 and B2) mesothelioma. The cohorts B1 will be patient populations with non-resected or incomp...
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10035605 Pleural mesothelioma malignant advanced LLT
    21.0 100000004864 10034669 Peritoneal mesothelioma malignant advanced LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2011-003618-18 Sponsor Protocol Number: M10-897 Start Date*: 2013-04-19
    Sponsor Name:Abbott GmbH & Co. KG
    Full Title: A Randomized, Double-Blind, Phase 2, Dose-Ranging Study to Evaluate the Safety and Efficacy of Veliparib and Whole Brain Radiation Therapy Versus Placebo and Whole Brain Radiation Therapy in Su...
    Medical condition: Brain metastases from NSCLC
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006128 Brain metastases LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NO (Completed) BE (Completed) CZ (Completed) FI (Completed) ES (Completed) HU (Completed)
    Trial results: View results
    EudraCT Number: 2008-005011-18 Sponsor Protocol Number: 09072008-13772 Start Date*: 2008-11-05
    Sponsor Name:Deutsche Krebsgesellschaft e.V.
    Full Title: A phase III randomized sequential open-label study to evaluate the efficacy and safety of sorafenib followed by sunitinib versus sunitinib followed by sorafenib in the treatment of first-line advan...
    Medical condition: First-line advanced / metastatic renal cell carcinoma
    Disease: Version SOC Term Classification Code Term Level
    9.1 10050513 Metastatic renal cell carcinoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) DE (Completed) AT (Completed)
    Trial results: View results
    EudraCT Number: 2019-001828-36 Sponsor Protocol Number: ABP-2019 Start Date*: 2020-02-21
    Sponsor Name:Institut für Klinische Krebsforschung IKF GmbH am Krankenhaus Nordwest
    Full Title: Advancing Brigatinib Properties in anaplastic lymphoma kinase positive non-small cell lung cancer (ALK+ NSCLC) patients by deep phenotyping
    Medical condition: Anaplastic lymphoma kinase positive non-small cell lung cancer (ALK+ NSCLC)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061873 Non-small cell lung cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2018-000454-22 Sponsor Protocol Number: CCR4825 Start Date*: 2019-02-01
    Sponsor Name:The Royal Marsden NHS Foundation Trust
    Full Title: A translational phase II study of single agent Olaparib in the treatment of advanced oesophagogastric cancer
    Medical condition: Advanced Oesophago-gastric cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2008-004438-25 Sponsor Protocol Number: 20060342 Start Date*: 2008-10-21
    Sponsor Name:Amgen Inc
    Full Title: A Randomized, Double-Blind, Placebo Controlled, Phase 2 Trial of Paclitaxel in Combination With AMG 386 in Subjects With Advanced Recurrent Epithelial Ovarian or Primary Peritoneal Cancer
    Medical condition: Advanced Recurrent Epithelial Ovarian or Primary Peritoneal Cance
    Disease: Version SOC Term Classification Code Term Level
    17.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066697 Ovarian cancer recurrent PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: BE (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Tue May 20 12:56:18 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA